Amgen is betting that convenience, not raw weight loss, can carve it a place in the crowded obesity drug market. The Thousand Oaks, California-based company is developing MariTide, an experimental therapy designed to be injected once a month, or potentially once every three months, instead of the weekly schedule that defines the current standard of care.
That difference is not trivial. Patients on Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound face 52 injections a year. If MariTide clears late-stage testing, that burden could fall to as few as 12 or even four shots annually.
The company said it began a Phase 3 trial in the third quarter that pits MariTide head-to-head against Novo Nordisk’s semaglutide, the active ingredient in Wegovy. Enrollment is also complete for two sleep apnea studies and a cardiovascular outcomes trial, and a first Phase 3 Type 2 diabetes study comparing MariTide with semaglutide is now recruiting. Two additional diabetes trials are slated to begin before the end of 2026.
“We delivered another strong quarter,” Chief Executive Robert Bradway said on the company’s earnings call, during which Amgen also lifted its full-year outlook.
A market built around weekly injections
Eli Lilly and Novo Nordisk currently dominate the category, and both rely on once-weekly dosing. That routine is a known weak point: a study published in the Journal of Managed Care Pharmacy found many patients abandon the drugs within a year, citing side effects, cost and the hassle of frequent injections. Amgen argues a monthly option could help patients who struggle with adherence, as well as those who live far from a pharmacy or travel frequently for work.
The commercial logic is straightforward, but the clinical bar is high. MariTide’s Phase 2 data showed roughly 20% average weight loss over a year, short of Zepbound’s results and well below the 28% reported for Lilly’s experimental candidate retatrutide. Truist Securities wrote earlier this year that MariTide “remains the focal point” for Amgen, while cautioning that its real-world value hinges on whether less frequent dosing holds up over long-term use.
Third-quarter results and pipeline dependence
Amgen’s third-quarter revenue climbed 8% to $10.4 billion, while non-GAAP earnings per share rose 14% to $6.45, topping the $5.79 consensus compiled by LSEG. The company raised its full-year adjusted earnings guidance to a range of $22.90 to $23.70 per share.
MetricQ3 resultComparisonRevenue$10.4 billionUp 8% year over yearNon-GAAP EPS$6.45Up 14%; consensus $5.79Full-year adjusted EPS guidance$22.90-$23.70RaisedRepatha sales$1.08 billionUp 37%UPLIZNA sales$451 millionUp 191%IMDELLTRA sales$406 millionUp 128%
Note: Consensus figure from LSEG data.
The quarter’s standout performers were the cholesterol drug Repatha, the rare autoimmune disease medicine UPLIZNA and the lung cancer therapy IMDELLTRA. Amgen already has 17 products on track to generate more than $1 billion in annual sales each, giving it a commercial base that does not depend on the obesity bet.
Even so, the stock’s next leg higher is tied closely to MariTide. Phase 3 readouts are expected in 2027, and if the results mirror Phase 2, Amgen may struggle to close the efficacy gap with Lilly and Novo Nordisk on weight loss alone.
What it means for investors
The stakes are large. Goldman Sachs expects the obesity market to reach $114 billion by 2030, and a monthly or quarterly injection could capture patients who currently avoid or abandon weekly therapy. Rivals are moving in the same direction: Pfizer has 10 late-stage weight-loss trials underway, including a monthly-shot program that produced 12% weight reduction in recent studies.
For Amgen, the setup is asymmetric. A diversified portfolio of marketed drugs cushions the downside, but the upside case rests almost entirely on whether MariTide can deliver competitive weight loss with a dosing schedule patients find easier to live with.